[{"id":"40df6160-751e-485f-9648-832a744ed37a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04077099","created_at":"2021-01-18T19:58:00.182Z","updated_at":"2024-07-02T16:35:16.114Z","phase":"Phase 1/2","brief_title":"REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04077099","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e davutamig (REGN5093)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 10/20/2024","primary_completion_date":" 10/20/2024","study_txt":" Completion: 10/20/2024","study_completion_date":" 10/20/2024","last_update_posted":"2024-03-06"}]